Nexien BioPharma, Inc. (NXEN) financial statements (2020 and earlier)

Company profile

Business Address 4340 E KENTUCKY AVE
GLENDALE, CO 80246
State of Incorp. DE
Fiscal Year End June 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2019
TTM
6/30/2019
6/30/2018
6/30/2017
6/30/2016
6/30/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments49146820   
Cash and cash equivalents49146820   
Receivables  15   
Other current assets865    
Other undisclosed current assets91100    
Total current assets:147311835   
Noncurrent Assets
Long-term investments and receivables  100   
Due from related parties  100   
Other undisclosed noncurrent assets  338   
Total noncurrent assets:  438   
TOTAL ASSETS:1473111,272   
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:18458912 2
Accrued liabilities   12 2
Other undisclosed accounts payable and accrued liabilities184589   
Due to related parties   60 40
Other undisclosed current liabilities   19707
Total current liabilities:184589927049
Noncurrent Liabilities
Total liabilities:184589927049
Stockholders' equity
Stockholders' equity attributable to parent, including:1282661,184(92)(70)(49)
Common stock554222
Additional paid in capital11,58311,5062,883000
Accumulated deficit(7,214)(5,776)(1,475)(94)(72)(51)
Other undisclosed stockholders' equity attributable to parent(4,246)(5,470)(229)   
Total stockholders' equity:1282661,184(92)(70)(49)
TOTAL LIABILITIES AND EQUITY:1473111,272   

Income statement (P&L) ($ in thousands)

12/31/2019
TTM
6/30/2019
6/30/2018
6/30/2017
6/30/2016
6/30/2015
Operating expenses(2,982)(4,301)(1,283)(16)(16)(47)
Other operating expense, net
(Other Expenses)
   (6)(5)(2)
Operating loss:(2,982)(4,301)(1,283)(22)(21)(48)
Interest and debt expense   (6)(5)(2)
Net loss:(2,982)(4,301)(1,283)(28)(26)(50)
Other undisclosed net income attributable to parent   652
Net loss available to common stockholders, diluted:(2,982)(4,301)(1,283)(22)(21)(48)

Comprehensive Income ($ in thousands)

12/31/2019
TTM
6/30/2019
6/30/2018
6/30/2017
6/30/2016
6/30/2015
Net loss:(2,982)(4,301)(1,283)(28)(26)(50)
Comprehensive loss, net of tax, attributable to parent:(2,982)(4,301)(1,283)(28)(26)(50)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: